The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has announced it is assessing new data on the potential risk of neurodevelopmental disorders (NDDs) in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Paternal use of ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has instructed healthcare organisations to immediately institute a plan for implementing the first phase of new regulatory measures to ...

Maternal use of valproate during pregnancy has been associated with an increased risk of neurodevelopmental disorders in children. Although most studies of other antiseizure medications have not shown ...

Other effective medicines are available for epilepsy and bipolar disorder and valproate should only be used if these don’t work or aren’t suitable for an individual patient. Image Credit: Medicines ...

Families of children harmed by a drug that caused up to 20,000 babies to be born with disabilities have welcomed calls for compensation after their plight was compared to the thalidomide scandal. The ...

tremor and parkinsonism. Following establishment of tolerability with oral risperidone, Uzedy may be started as a once monthly injection for monotherapy or adjunctive therapy to lithium or valproate ...